Who Paid My Doc
Zynteglo
Drug beta-thalassemia
NDC 73554-3111-1
General payments
$357,956
Research payments
$3,464,343
Through program year 2025, $357,956 in general payments and $3,464,343 in research payments were reported against Zynteglo (beta-thalassemia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,631,083 | 96 |
| 2024 | General | $145,697 | 84 |
| 2024 | Research | $1,010,608 | 24 |
| 2023 | General | $212,259 | 137 |
| 2023 | Research | $822,652 | 50 |
Breakdown
The top 5 of 56 recipients; each share is of general payments naming this product in 2024.
The top 5 of 16 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 15 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
221 general · 170 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.